<!DOCTYPE html>
<html lang="en" dir="ltr">

<head>
  <title>IgAN Patient Case - About Carlos's Experience</title>
  <meta name="description" content="Discover Carlosâ€™s experience with IgAN. Follow his case to see how this chronic kidney condition can lead to end-stage kidney disease">
  {{> ../templates/header }}
  <link href="../styles.bundle.css" rel="stylesheet" type="text/css">
</head>

<body>
  <!-- Google Tag Manager (noscript) -->
  <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-WZLFQZR3" height="0" width="0"
      style="display:none;visibility:hidden"></iframe></noscript>
  <!-- End Google Tag Manager (noscript) -->
  <main class="wrapper" data-page-id="pat-profile-carlos" data-path-level="2">

    {{> ../templates/nav }}
    {{> ../templates/interstitial }}

    <div class="progress-dots-container"></div>

    {{> ../templates/mestc-score-modal }}

    <img id="scroll-arrow" class="update-path" src="./assets/images/scroll-arrow.svg" alt="Scroll arrow down" />

    <div id="mobile-bio-tray" class="mobile-bio-tray">
      <div id="tray-close">
        <p>Baseline Assessment at Biopsy</p>
        <img src="./assets/images/back-arrow.svg" class="update-path arrow" alt="Back arrow"/>
      </div>

      <p class="name">Carlos, 40</p>

      {{> ../templates/carlos-bio }}

      <div class="extra-section">
        <p class="extra-footnote">*Image used with permission from the Renal Fellow Network, from: Gallan A. Kidney Biopsy of the Month.
          Published July 29, 2019. Available at <a class="format-url link-color" target="_blank"
            href="https://www.renalfellow.org/2019/07/29/kidney-biopsy-of-the-month-iga-nephropathy/">https://www.renalfellow.org/2019/07/29/kidney-biopsy-of-the-month-iga-nephropathy/</a>.
        </p>
    
        <p class="extra-footnote">ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BP, blood pressure; CKD, chronic kidney disease; eGFR,
          estimated glomerular filtration rate; IgA, immunoglobulin A; MEST-C, mesangial hypercellularity (M), endocapillary
          hypercellularity (E), segmental sclerosis (S), tubular atrophy and interstitial fibrosis (T), crescent
          (C); PAS, periodic acid-Schiff.</p>
      </div>
    </div>

    <div id="carlos-bio-tray-2" class="mobile-bio-tray">
      <div id="tray-close">
        <p>Assessment after 2 years</p>
        <img src="./assets/images/back-arrow.svg" class="update-path arrow" alt="Back arrow"/>
      </div>

      <p class="name">Carlos, 42</p>

      {{> ../templates/carlos-bio-42 }}

      <div class="extra-section">
        <p class="extra-footnote">*Image used with permission from the Renal Fellow Network, from: Gallan A. Kidney Biopsy of the Month.
          Published July 29, 2019. Available at <a class="format-url link-color" target="_blank"
            href="https://www.renalfellow.org/2019/07/29/kidney-biopsy-of-the-month-iga-nephropathy/">https://www.renalfellow.org/2019/07/29/kidney-biopsy-of-the-month-iga-nephropathy/</a>.
        </p>
    
        <p class="extra-footnote">ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BP, blood pressure; CKD, chronic kidney disease; eGFR,
          estimated glomerular filtration rate; IgA, immunoglobulin A; MEST-C, mesangial hypercellularity (M), endocapillary
          hypercellularity (E), segmental sclerosis (S), tubular atrophy and interstitial fibrosis (T), crescent
          (C); PAS, periodic acid-Schiff.</p>
      </div>
    </div>

    <!-- //////////////////// SECTION 1 ///////////////////// -->

    <section class="" data-section-id="1" data-section-name="Carlos Patient Information" data-dot-label="Meet Carlos">
      <div class="two-column">

        <div id="left-bio">
          <img src="./assets/images/profiles/carlos-profile.png" class="update-path bio-pic"
            alt="" />
          
            {{> ../templates/carlos-bio }}
        </div>

        <div class="right-side">
          <img src="./assets/images/profiles/carlos-profile.png" class="update-path bio-pic conditional-render" alt=""/>
          <p class="name conditional-render">Carlos, 40</p>

          <h1 class="sect-1-header">Carlos is a 40-year-old Hispanic man and<br class="extra-wide-only" /> IT professional who runs his own
            business.</h1>

          <p class="bold">Over the past 3 months, Carlos began experiencing fatigue, weight gain, and swelling in his
            ankles, which he noticed because his shoes were fitting more tightly than usual. Carlos remembers when he
            was a child, his father experienced similar symptoms of fatigue and swollen ankles.</p>

          <ul class="bullet-list">
            <li><span class="bullet">&bull;</span><span>High blood pressure and grade 2 edema were found upon physical
                exam</span></li>
          </ul>

          <div class="divider"></div>

          <h4 class="purple">Carlos followed up with a nephrologist</h4>

          <div class="flex">
            <div class="workup">
              <img class="icon update-path" src="./assets/images/gauge-icon.svg" alt="" />
              <p>Reduced renal function<br class="desktop-only" /> suggesting stage 3a CKD</p>
            </div>
            <div class="workup">
              <img class="icon update-path" src="./assets/images/vial-icon.svg" alt="" />
              <p>Microscopic hematuria,<br class="desktop-only" /> and proteinuria of 6 g/d</p>
            </div>
          </div>
          <div class="flex">
            <div class="workup">
              <img class="icon update-path" src="./assets/images/kidneys-icon.svg" alt="" />
              <p>Kidney biopsy with staining revealed IgA deposits, mesangial and
                endocapillary <br class="desktop-only" />hypercellularity, and segmental sclerosis, confirming a
                diagnosis of IgAN</p>
            </div>
          </div>

          <p class="direction bold align-center tablet-desktop-only">Click the arrows in the carousel below to explore Carlos&rsquo; baseline characteristics</p>
        </div>

      </div>
    </section>

    <div class="temp-section mobile-only">
      <p class="direction bold align-center">Swipe in the carousel below to explore Carlos&rsquo; baseline characteristics</p>
    </div>

    <!-- //////////////////// SECTION 2 ///////////////////// -->

    <section class="" data-section-id="2" data-section-name="Carlos Demographic and Information Carousel" data-dot-label="Baseline<br>Characteristics">
      <div class="owl-carousel">
        <div class="carousel-block" id="carlos-block-1">
          <h3 class="label">Age at Biopsy</h3>
          <h4 class="characteristic">40 years old</h4>

          <ul class="bullet-list">
            <li><span class="bullet">&bull;</span><span>Most patients with IgAN are diagnosed by 40 years of
                age<sup>1</sup></span></li>
            <li><span class="bullet">&bull;</span><span>Clinical presentation and disease progression can vary based on
                the patient&rsquo;s age at diagnosis<sup>2</sup></span></li>
          </ul>

          <div class="footnotes">
            <p><span class="bold">References: 1.</span> Pitcher D, et al. <em>Clin J Am Soc Nephrol</em>.
              2023;18(6):727-738. <br class="large-screens-only"><span class="bold">2.</span> Gutierrez E, et al. <em>Nephrol Dial Transplant</em>.
              2018;33:472-477.</p>
          </div>
        </div>

        <div class="carousel-block" id="carlos-block-2">
          <h3 class="label">Race</h3>
          <h4 class="characteristic">Hispanic</h4>

          <ul class="bullet-list">
            <li><span class="bullet">&bull;</span><span>Clinical presentation and progression of IgAN can vary greatly
                depending on ethnicity<sup>1</sup></span></li>
            <li><span class="bullet">&bull;</span><span>Hispanic patients with IgAN have a high rate of CKD progression
                and ESKD, with a median age at ESKD of 46 years<sup>2</sup></span></li>
          </ul>

          <div class="footnotes">
            <p>CKD, chronic kidney disease; ESKD, end-stage kidney disease.</p>
            <p><span class="bold">References: 1.</span> Yeo SC, et al. <em>Nephrology (Carlton)</em>.
              2019;24(9):885-895. <span class="bold">2.</span> Sim J, et al. <em>Nephrol Dial Transplant</em>. 2025:gfaf084.</p>
          </div>
        </div>

        <div class="carousel-block" id="carlos-block-3">
          <h3 class="label">Estimated GFR at Biopsy</h3>
          <h4 class="characteristic">47 mL/min/<br class="mobile-only"/>1.73 m<sup>2</sup></h4>

          <ul class="bullet-list">
            <li><span class="bullet">&bull;</span><span>Carlos&rsquo; eGFR at biopsy indicated that he was in Stage 3a
                CKD: some kidney damage causing a mild to moderate loss of kidney function</span></li>
            <li><span class="bullet">&bull;</span><span>eGFR decline is a validated risk factor of IgAN progression.
                Declines in eGFR are strongly associated with the risk of CKD progression and
                mortality<sup>1</sup></span></li>
          </ul>

          <div class="footnotes">
            <p>CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate.</p>
            <p><span class="bold">Reference: 1.</span> Coresh J, et al. <em>JAMA</em>. 2014;311(24):2518-2531.</p>
          </div>
        </div>

        <div class="carousel-block" id="carlos-block-4">
          <h3 class="label">Blood Pressure at Biopsy</h3>
          <h4 class="characteristic">160/84 mm Hg</h4>

          <ul class="bullet-list">
            <li><span class="bullet">&bull;</span><span>Carlos&rsquo; blood pressure was found to be elevated at
                biopsy</span></li>
            <li><span class="bullet">&bull;</span><span>Hypertension has been shown to serve as a clinical predictor of
                IgAN progression at the time of diagnosis<sup>1</sup></span></li>
            <li><span class="bullet">&bull;</span><span>Reduction of hypertension lowers the risk of progression to
                kidney failure<sup>2</sup></span></li>
          </ul>

          <div class="footnotes">
            <p><span class="bold">References: 1.</span> Maixnerova D, et al. <em>J Nephrol</em>. 2016;29(4):535-541.
              <span class="bold">2.</span> KDIGO. <em>Kidney Int</em>. 2021;100:S1-S276.</p>
          </div>
        </div>

        <div class="carousel-block" id="carlos-block-5">
          <h3 class="label">Proteinuria at Biopsy</h3>
          <h4 class="characteristic">6 g/d</h4>

          <ul class="bullet-list">
            <li><span class="bullet">&bull;</span><span>Carlos had elevated proteinuria at the time of biopsy</span>
            </li>
            <li><span class="bullet">&bull;</span><span>Proteinuria is a validated prognostic marker linked to
                long-term kidney outcomes, including eGFR decline and ESKD<sup>1,2</sup></span></li>
            <li><span class="bullet">&bull;</span><span>Proteinuria reduction inversely correlates with serum
                creatinine doubling, ESKD, and death<sup>2,3</sup></span></li>
          </ul>

          <div class="footnotes">
            <p>eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease.</p>
            <p><span class="bold">References: 1.</span> KDIGO. <em>Kidney Int</em>. 2021;100:S1-S276. <span
                class="bold">2.</span> Thompson A, et al. <em>Clin J Am Soc Nephrol</em>. 2019;14(3):469-481. <span
                class="bold">3.</span> Inker L, et al. <em>Am J Kidney Dis</em>. 2016;68(3):392-401.</p>
          </div>
        </div>

        <div class="carousel-block" id="carlos-block-6">
          <h3 class="label">ACE<span class="lower">i</span>/ARB Use at the Time of Biopsy</h3>
          <h4 class="characteristic">None</h4>

          <p>While ACEi/ARBs are recommended as part of supportive care, Carlos had not initiated treatment at the time
            of his biopsy.<sup>1</sup></p>

          <div class="footnotes">
            <p>ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.</p>
            <p><span class="bold">Reference: 1.</span> KDIGO. <em>Kidney Int</em>. 2021;100:S1-S276.</p>
          </div>
        </div>

        <div class="carousel-block" id="carlos-block-7">
          <h3 class="label">MEST-C Score</h3>
          <h4 class="characteristic">M1 E1 S1 T0 C0</h4>

          <p>Carlos&rsquo; biopsy was evaluated using the Oxford classification, or MEST-C score. His biopsy showed
            mesangial hypercellularity in &gt;50% of glomeruli, presence of endocapillary hypercellularity and segmental
            glomerulosclerosis, and no tubular atrophy/interstitial fibrosis or crescents.</p>
          <p>The MEST-C score can serve as a valuable early prognostic tool and should be considered when evaluating the
            risk of progression to ESKD.<sup>1-3</sup></p>

          <div class="button cta modal-trigger" data-trigger-id="mest-c-score">
            <p>Learn more about MEST-C</p>
          </div>

          <div class="footnotes">
            <p>ESKD, end-stage kidney disease; MEST-C, mesangial hypercellularity (M), endocapillary hypercellularity
              (E), segmental sclerosis (S), tubular atrophy and interstitial fibrosis (T), crescent (C).</p>
            <p><span class="bold">References: 1.</span> Cattran DC, et al. <em>Kidney Int Rep</em>.
              2023;8(12):2515-2528. <span class="bold">2.</span> Haaskjold YL, et al. <em>BMC Nephrology</em>.
              2022;23:26. <span class="bold">3.</span> Coppo R, et al. <em>Kidney Int</em>. 2014;86(4):828-836.</p>
          </div>
        </div>

        <div class="carousel-block" id="carlos-block-8">
          <h3 class="label">Immunosuppression Use at or Prior to Biopsy </h3>
          <h4 class="characteristic">None</h4>

          <p>While the clinical benefits of immunosuppressive therapy have not been established in patients with IgAN,
            they may be used in specific patient populations if the risk/benefit profile is acceptable.<sup>1</sup></p>

          <div class="footnotes">
            <p><span class="bold">Reference: 1.</span> KDIGO. <em>Kidney Int</em>. 2021;100:S1-S276.</p>
          </div>
        </div>
      </div>

    </section>

    <div class="temp-section">
      <div class="footnotes">
        <p>*Image used with permission from the Renal Fellow Network, from: Gallan A. Kidney Biopsy of the Month.
          Published July 29, 2019. Available at <a class="format-url link-color" target="_blank"
            href="https://www.renalfellow.org/2019/07/29/kidney-biopsy-of-the-month-iga-nephropathy/">https://www.renalfellow.org/2019/07/29/kidney-biopsy-of-the-month-iga-nephropathy/</a>.
        </p>
    
        <p>ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BP, blood pressure; CKD, chronic kidney disease; eGFR,
          estimated glomerular filtration rate; IgA, immunoglobulin A; MEST-C, mesangial hypercellularity (M), endocapillary
          hypercellularity (E), segmental sclerosis (S), tubular atrophy and interstitial fibrosis (T), crescent
          (C); PAS, periodic acid-Schiff.</p>
      </div>

      <img class="tablet-only update-path mobile-bio-trigger" id="mobile-bio-trigger" data-tray-id="mobile-bio-tray" src="./assets/images/profiles/mobile-bio-btn.png" alt="Baseline Assessment trigger button"/>
    </div>

    <section class="gray-bg" data-section-id="3" data-section-name="Carlos' Risk of Progression" data-dot-label="Risk of<br>Progression">
      <div class="two-column static">

        <div id="left-bio" class="">
          <img src="./assets/images/profiles/carlos-profile.png" class="update-path bio-pic" alt="" />

          {{> ../templates/carlos-bio }}
        </div>

        <div class="right-side dual-view">
          <h1 class="pat-header">Carlos&rsquo; Risk of Progression</h1>
          <p class="desc-text">Based on Carlos&rsquo; clinical features at the time of his biopsy, he may be at risk of developing kidney failure before he turns 50.</p>

          <div class="graph-container">
            <div class="hotspot" id="state-1" data-value="Age 41;2%"></div>
            <div class="hotspot" id="state-2" data-value="Age 42;7%"></div>
            <div class="hotspot" id="state-3" data-value="Age 43;12%"></div>
            <div class="hotspot" id="state-4" data-value="Age 44;18%"></div>
            <div class="hotspot" id="state-5" data-value="Age 45;25%"></div>

            <div class="tablet-desktop-only">
              <img src="./assets/images/profiles/carlos/progression-graph-state-0.png" id="state-0"
                class="graph update-path" alt="Graph showing Carlos' risk of progression" />
              <img src="./assets/images/profiles/carlos/progression-graph-state-1.png" id="state-1"
                class="graph visible update-path" alt="Graph showing Carlos' risk of progression at age 41. 2 percent 1 year after biopsy" />
              <img src="./assets/images/profiles/carlos/progression-graph-state-2.png" id="state-2"
                class="graph update-path" alt="Graph showing Carlos' risk of progression at age 42. 7 percent 2 years after biopsy" />
              <img src="./assets/images/profiles/carlos/progression-graph-state-3.png" id="state-3"
                class="graph update-path" alt="Graph showing Carlos' risk of progression at age 43. 12 percent 3 years after biopsy" />
              <img src="./assets/images/profiles/carlos/progression-graph-state-4.png" id="state-4"
                class="graph update-path" alt="Graph showing Carlos' risk of progression at age 44. 18 percent 4 years after biopsy" />
              <img src="./assets/images/profiles/carlos/progression-graph-state-5.png" id="state-5"
                class="graph update-path" alt="Graph showing Carlos' risk of progression at age 45. 25 percent 5 years after biopsy" />
            </div>
            <div class="mobile-only">
              <img src="./assets/images/profiles/carlos/mobile/progression-graph-state-0-mobile.png" id="state-0"
                class="graph mobile-graph update-path" alt="Graph showing Carlos' risk of progression" />
              <img src="./assets/images/profiles/carlos/mobile/progression-graph-state-1-mobile.png" id="state-1"
                class="graph mobile-graph visible update-path" alt="Graph showing Carlos' risk of progression at age 41. 2 percent 1 year after biopsy" />
              <img src="./assets/images/profiles/carlos/mobile/progression-graph-state-2-mobile.png" id="state-2"
                class="graph mobile-graph update-path" alt="Graph showing Carlos' risk of progression at age 42. 7 percent 2 years after biopsy" />
              <img src="./assets/images/profiles/carlos/mobile/progression-graph-state-3-mobile.png" id="state-3"
                class="graph mobile-graph update-path" alt="Graph showing Carlos' risk of progression at age 43. 12 percent 3 years after biopsy" />
              <img src="./assets/images/profiles/carlos/mobile/progression-graph-state-4-mobile.png" id="state-4"
                class="graph mobile-graph update-path" alt="Graph showing Carlos' risk of progression at age 44. 18 percent 4 years after biopsy" />
              <img src="./assets/images/profiles/carlos/mobile/progression-graph-state-5-mobile.png" id="state-5"
                class="graph mobile-graph update-path" alt="Graph showing Carlos' risk of progression at age 45. 25 percent 5 years after biopsy" />
            </div>
          </div>

          <a href="https://qxmd.com/calculate/calculator_499/international-igan-prediction-tool-at-biopsy-adults"
          target="_blank">
            <div class="button cta" id="sect-3-tool-exit">
              <p>View the International <br class="mobile-only"/>IgAN Prediction Tool</p>
              <img src="./assets/images/external-icon-white.svg" class="update-path" alt="External link icon" />
            </div>
          </a>
        </div>
      </div>

      <div class="footnotes">
        <p><sup>a</sup>Predicted risk of progression was calculated using the International IgAN Prediction Tool and
          defined as the risk of a 50% decline in eGFR or ESKD.<sup>1</sup></p>
        <p>*Image used with permission from the Renal Fellow Network, from: Gallan A. Kidney Biopsy of the Month.
          Published July 29, 2019. Available at <a class="format-url link-color" target="_blank"
            href="https://www.renalfellow.org/2019/07/29/kidney-biopsy-of-the-month-iga-nephropathy/">https://www.renalfellow.org/2019/07/29/kidney-biopsy-of-the-month-iga-nephropathy/</a>.
        </p>
        <p>ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BP, blood pressure; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; MEST-C, mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental sclerosis (S), tubular atrophy and interstitial fibrosis (T), crescent (C); PAS, periodic acid-Schiff.</p>
        <p><span class="bold">Reference: 1.</span> Barbour SJ, et al. <em>Kidney Int</em>. 2022;102(1):160-172.</p>
      </div>

      <img class="tablet-only update-path mobile-bio-trigger" id="mobile-bio-trigger-2" data-tray-id="carlos-bio-tray-2" src="./assets/images/profiles/mobile-bio-btn-2.png" alt="Baseline Assessment After 2 Years trigger button"/>
    </section>

    <section class="" data-section-id="4" data-section-name="Carlos' Risk of Progression After Supportive Care" data-dot-label="After<br>Supportive care">
      <div class="two-column static">
        <div id="left-bio" class="">
          <img src="./assets/images/profiles/carlos-profile.png" class="update-path bio-pic" alt="" />

          {{> ../templates/carlos-bio-42 }}
        </div>

        <div class="right-side">
          <h1 class="pat-header">Carlos&rsquo; Risk of Progression<br class="desktop-only" /> After Supportive Care</h1>

          <p class="desc-text">Carlos was promptly started on maximal supportive care including immunosuppression. Two
            years after his initial diagnosis, he was able to reduce his blood pressure and reduce his proteinuria by
            half to 3 g/d.</p>

          <div class="graph-container">
            <div class="hotspot" id="state-1" data-value="Age 43;5%"></div>
            <div class="hotspot" id="state-2" data-value="Age 44;16%"></div>
            <div class="hotspot" id="state-3" data-value="Age 45;26%"></div>
            <div class="hotspot" id="state-4" data-value="Age 46;36%"></div>
            <div class="hotspot" id="state-5" data-value="Age 47;46%"></div>

            <div class="tablet-desktop-only">
              <img src="./assets/images/profiles/carlos/progression-graph-2-years-state-0.png" id="state-0"
                class="graph update-path"
                alt="Graph showing Carlos' risk of progression one year after stabilization on supportive care" />
              <img src="./assets/images/profiles/carlos/progression-graph-2-years-state-1.png" id="state-1"
                class="graph visible update-path"
                alt="Graph showing Carlos' risk of progression at age 43. 5 percent risk one year after stabilization on supportive care" />
              <img src="./assets/images/profiles/carlos/progression-graph-2-years-state-2.png" id="state-2"
                class="graph update-path"
                alt="Graph showing Carlos' risk of progression at age 44. 16 percent risk two years after stabilization on supportive care" />
              <img src="./assets/images/profiles/carlos/progression-graph-2-years-state-3.png" id="state-3"
                class="graph update-path"
                alt="Graph showing Carlos' risk of progression at age 45. 26 percent risk three years after stabilization on supportive care" />
              <img src="./assets/images/profiles/carlos/progression-graph-2-years-state-4.png" id="state-4"
                class="graph update-path"
                alt="Graph showing Carlos' risk of progression at age 46. 36 percent risk four years after stabilization on supportive care" />
              <img src="./assets/images/profiles/carlos/progression-graph-2-years-state-5.png" id="state-5"
                class="graph update-path"
                alt="Graph showing Carlos' risk of progression at age 47. 46% risk five years after stabilization on supportive care" />
            </div>
            <div class="mobile-only">
              <img src="./assets/images/profiles/carlos/mobile/progression-graph-2-years-state-0-mobile.png" id="state-0"
                class="mobile-graph graph update-path"
                alt="Graph showing Carlos' risk of progression one year after stabilization on supportive care" />
              <img src="./assets/images/profiles/carlos/mobile/progression-graph-2-years-state-1-mobile.png" id="state-1"
                class="mobile-graph graph visible update-path"
                alt="Graph showing Carlos' risk of progression at age 43. 5 percent risk one year after stabilization on supportive care" />
              <img src="./assets/images/profiles/carlos/mobile/progression-graph-2-years-state-2-mobile.png" id="state-2"
                class="mobile-graph graph update-path"
                alt="Graph showing Carlos' risk of progression at age 44. 16 percent risk two years after stabilization on supportive care" />
              <img src="./assets/images/profiles/carlos/mobile/progression-graph-2-years-state-3-mobile.png" id="state-3"
                class="mobile-graph graph update-path"
                alt="Graph showing Carlos' risk of progression at age 45. 26 percent risk three years after stabilization on supportive care" />
              <img src="./assets/images/profiles/carlos/mobile/progression-graph-2-years-state-4-mobile.png" id="state-4"
                class="mobile-graph graph update-path"
                alt="Graph showing Carlos' risk of progression at age 46. 36 percent risk four years after stabilization on supportive care" />
              <img src="./assets/images/profiles/carlos/mobile/progression-graph-2-years-state-5-mobile.png" id="state-5"
                class="mobile-graph graph update-path"
                alt="Graph showing Carlos' risk of progression at age 47. 46% risk five years after stabilization on supportive care" />
            </div>
          </div>

          <h4>Although he began treatment with supportive care soon after<br class="desktop-only" /> his diagnosis,
            Carlos&rsquo; risk of progression has increased.</h4>

          <p class="bold">Current KDIGO guidelines do not recommend SGLT2i use in IgAN in the absence of diabetes, as
            additional data are needed to assess efficacy and safety. Treatments in hypothetical patient cases reflect
            current treatment guidelines.<sup>2</sup></p>
        </div>

      </div>

      <div class="footnotes">
        <p>*Image used with permission from the Renal Fellow Network, from: Gallan A. Kidney Biopsy of the Month.
          Published July 29, 2019. Available at <a class="format-url link-color" target="_blank"
            href="https://www.renalfellow.org/2019/07/29/kidney-biopsy-of-the-month-iga-nephropathy/">https://www.renalfellow.org/2019/07/29/kidney-biopsy-of-the-month-iga-nephropathy/</a>.
        </p>
        <p><sup>a</sup>MEST-C score obtained from initial baseline biopsy</p>
        <p><sup>b</sup>Predicted risk of progression was calculated using the International IgAN Prediction Tool and
          defined as the risk of a 50% decline in eGFR or ESKD.<sup>1</sup></p>
        <p>ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BP, blood pressure; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; KDIGO, Kidney Disease Improving Global Outcomes; MEST-C, mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental sclerosis (S), tubular atrophy and interstitial fibrosis (T), crescent (C); PAS, periodic acid-Schiff; SGLT2i, sodium-glucose transport protein 2 inhibitor.</p>
        <p><span class="bold">References: 1.</span> Barbour SJ, et al. <em>Kidney Int</em>. 2022;102(1):160-172. <span
            class="bold">2.</span> KDIGO. <em>Kidney Int</em>. 2021;100:S1-S276.</p>
      </div>
    </section>

    <section class="gray-bg" data-section-id="5" data-section-name="Carlos Histopathological Changes Caused by IgAN" data-dot-label="Histopathological<br>Changes">
      <div class="flex-header">
        <img src="./assets/images/profiles/carlos-profile.png" class="update-path bio-pic desktop-only" alt="" />

        <div>
          <h1 class="pat-header">Histopathological Changes<br class="desktop-only" /> Caused by IgAN</h1>
          <p class="desc-text">Carlos was able to lower his proteinuria and blood pressure; however,
            Gd-IgA1 immune complexes can continue to deposit in his kidneys, causing histopathological changes and
            kidney damage.<sup>1</sup></p>
        </div>
      </div>

      <div class="content-lower">
        <p class="subhead">Patients with IgAN may continue to lose functional kidney tissue over time even when treated
          with supportive care to improve other clinical parameters like blood pressure and/or proteinuria.<sup>2</sup>
        </p>

        <div class="divider"></div>

        <h3 class="graph-header">Changes in renal histopathological features</h3>
        <p class="direction">Use the slider to see how histopathological features can change over time and impact kidney
          survival.</p>

        <div class="images-container">
          <div class="left-side">
            <div class="text-bubble visible" id="section-5-state-1">
              <p>At biopsy, Carlos had mesangial and endocapillary hypercellularity. Part of the glomerulus had
                developed sclerosis as indicated by the black arrow in the image below.<sup>a</sup></p>

              <div class="gap-10"></div>

              <img src="./assets/images/profiles/carlos/biopsy-stain.png" class="stain update-path"
                alt="PAS staining showing sclerosis in the upper left portion of the glomerulus as indicated by a black arrow." />

              <div class="gap-10"></div>

              <p>Image used with permission*</p>
            </div>

            <div class="text-bubble" id="section-5-state-2">
              <p>Mesangial and endocapillary cells continue to proliferate, and the glomerulus has developed more
                scarring.</p>
            </div>

            <div class="text-bubble" id="section-5-state-3">
              <p>Excess ECM is deposited within the mesangium, and tubular atrophy develops.</p>
            </div>

            <div class="text-bubble" id="section-5-state-4">
              <p>Mesangial cells and inflammatory cells continue to proliferate, and scarring spreads to more of the
                glomerulus.</p>
            </div>
          </div>

          <div class="right-side">
            <div class="graphic-container">
              <img src="./assets/images/profiles/carlos/graphic-1.png" id="section-5-state-1" class="update-path graphic visible" 
                alt="Detailed glomerulus structure with mesangial hypercellularity, endocapillary hypercellularity, and segmental sclerosis" />
              <img src="./assets/images/profiles/carlos/graphic-2.png" id="section-5-state-2" class="update-path graphic"
                alt="Detailed glomerulus structure with excess mesangial cells and immune cells" />
              <img src="./assets/images/profiles/carlos/graphic-3.png" id="section-5-state-3" class="update-path graphic"
                alt="Kidney structure showing glomerulosclerosis and tubular atrophy" />
              <img src="./assets/images/profiles/carlos/graphic-4.png" id="section-5-state-4" class="update-path graphic"
                alt="Glomerulus showing sclerosis, mesangial cell proliferation, and immune cells" />

                <div class="histo-tag group-1" id="tag-1">
                  <p>Protein</p>
                  <img src="./assets/images/plus-icon.svg" alt="" class="plus update-path"/>
                  <img src="./assets/images/x-icon.svg" alt="" class="close update-path"/>
                </div>
                <div class="histo-tag group-1" id="tag-2">
                  <p>Sclerosis</p>
                  <img src="./assets/images/plus-icon.svg" alt="" class="plus update-path"/>
                  <img src="./assets/images/x-icon.svg" alt="" class="close update-path"/>
                </div>
                <div class="histo-tag group-1" id="tag-3">
                  <p>Red blood cell</p>
                  <img src="./assets/images/plus-icon.svg" alt="" class="plus update-path"/>
                  <img src="./assets/images/x-icon.svg" alt="" class="close update-path"/>
                </div>
                <div class="histo-tag group-1" id="tag-4">
                  <p>ECM</p>
                  <img src="./assets/images/plus-icon.svg" alt="" class="plus update-path"/>
                  <img src="./assets/images/x-icon.svg" alt="" class="close update-path"/>
                </div>
                <div class="histo-tag group-1" id="tag-5">
                  <p>Gd-IgA1 immune <br class="mobile-only"/>complexes</p>
                    <img src="./assets/images/plus-icon.svg" alt="" class="plus update-path"/>
                    <img src="./assets/images/x-icon.svg" alt="" class="close update-path"/>
                </div>
                <div class="histo-tag group-1" id="tag-6">
                  <p>Immune cells</p>
                  <img src="./assets/images/plus-icon.svg" alt="" class="plus update-path"/>
                  <img src="./assets/images/x-icon.svg" alt="" class="close update-path"/>
                </div>
                <div class="histo-tag group-1" id="tag-7">
                  <p>Mesangial cells</p>
                    <img src="./assets/images/plus-icon.svg" alt="" class="plus update-path"/>
                    <img src="./assets/images/x-icon.svg" alt="" class="close update-path"/>
                </div>
                <div class="histo-tag group-3 hidden" id="tag-8">
                  <p>Tubular atrophy</p>
                    <img src="./assets/images/plus-icon.svg" alt="" class="plus update-path"/>
                    <img src="./assets/images/x-icon.svg" alt="" class="close update-path"/>
                </div>
            </div>

            <div class="slider-container conditional-slider-upper">
              <img src="./assets/images/profiles/over-time-slider-1.svg" id="section-5-state-1"
                class="update-path slider-upper slider visible" alt="Slider shown at biopsy stage">
              <img src="./assets/images/profiles/over-time-slider-2.svg" id="section-5-state-2"
                class="update-path slider-upper slider" alt="Slider shown at 2 years">
              <img src="./assets/images/profiles/over-time-slider-3.svg" id="section-5-state-3"
                class="update-path slider-upper slider" alt="Slider shown at 4 years">
              <img src="./assets/images/profiles/over-time-slider-4.svg" id="section-5-state-4"
                class="update-path slider-upper slider" alt="Slider shown at 6 years">

              <input type="range" class="range-slider" id="s6-upper" name="s6-upper" min="1" max="4" value="1" step="1" />
            </div>
          </div>
        </div>

        <div class="slider-container mobile-only">
          <img src="./assets/images/profiles/over-time-slider-1-mobile.png" id="section-5-state-1"
            class="update-path slider-upper mobile-graph slider visible" alt="Slider shown at biopsy stage">
          <img src="./assets/images/profiles/over-time-slider-2-mobile.png" id="section-5-state-2"
            class="update-path slider-upper mobile-graph slider" alt="Slider shown at 2 years">
          <img src="./assets/images/profiles/over-time-slider-3-mobile.png" id="section-5-state-3"
            class="update-path slider-upper mobile-graph slider" alt="Slider shown at 4 years">
          <img src="./assets/images/profiles/over-time-slider-4-mobile.png" id="section-5-state-4"
            class="update-path slider-upper mobile-graph slider" alt="Slider shown at 6 years">

          <input type="range" class="range-slider" id="s6-mobile" name="s6-mobile" min="1" max="4" value="1" step="1" />
        </div>

        <div class="slider-container conditional-slider-lower">
          <img src="./assets/images/profiles/over-time-slider-1.svg" id="section-5-state-1"
            class="update-path slider-upper graph slider visible" alt="Slider shown at biopsy stage">
          <img src="./assets/images/profiles/over-time-slider-2.svg" id="section-5-state-2"
            class="update-path slider-upper graph slider" alt="Slider shown at 2 years">
          <img src="./assets/images/profiles/over-time-slider-3.svg" id="section-5-state-3"
            class="update-path slider-upper graph slider" alt="Slider shown at 4 years">
          <img src="./assets/images/profiles/over-time-slider-4.svg" id="section-5-state-4"
            class="update-path slider-upper graph slider" alt="Slider shown at 6 years">

          <input type="range" class="range-slider" id="s6-conditional" name="s6-conditional" min="1" max="4" value="1" step="1" />
        </div>

        <div class="graphs-container">
          <div class="left-side">
            <div class="tablet-desktop-only">
              <img src="./assets/images/profiles/carlos/pro-over-time-state-1.png" id="section-5-state-1"
                class="update-path graph visible" alt="Graph modeling proteinuria progression over time, starting at biopsy"/>
              <img src="./assets/images/profiles/carlos/pro-over-time-state-2.png" id="section-5-state-2"
                class="update-path graph" alt="Graph showing proteinuria progression level after two years"/>
              <img src="./assets/images/profiles/carlos/pro-over-time-state-3.png" id="section-5-state-3"
                class="update-path graph" alt="Graph showing proteinuria progression level at four years"/>
              <img src="./assets/images/profiles/carlos/pro-over-time-state-4.png" id="section-5-state-4"
                class="update-path graph" alt="Graph showing proteinuria progression level at six years"/>
            </div>
            <div class="mobile-only">
              <img src="./assets/images/profiles/carlos/mobile/pro-over-time-state-1-mobile.png" id="section-5-state-1"
                class="update-path mobile-graph graph visible" alt="Graph modeling proteinuria progression over time, starting at biopsy"/>
              <img src="./assets/images/profiles/carlos/mobile/pro-over-time-state-2-mobile.png" id="section-5-state-2"
                class="update-path mobile-graph graph" alt="Graph showing proteinuria progression level after two years"/>
              <img src="./assets/images/profiles/carlos/mobile/pro-over-time-state-3-mobile.png" id="section-5-state-3"
                class="update-path mobile-graph graph" alt="Graph showing proteinuria progression level at four years"/>
              <img src="./assets/images/profiles/carlos/mobile/pro-over-time-state-4-mobile.png" id="section-5-state-4"
                class="update-path mobile-graph graph" alt="Graph showing proteinuria progression level at six years"/>
            </div>
          </div>
          <div class="right-side">
            <div class="tablet-desktop-only">
              <img src="./assets/images/profiles/carlos/egfr-over-time-state-1.png" id="section-5-state-1"
                class="update-path graph visible" alt="Graph modeling eGFR decline over time, starting at biopsy"/>
              <img src="./assets/images/profiles/carlos/egfr-over-time-state-2.png" id="section-5-state-2"
                class="update-path graph" alt="Graph showing eGFR after two years"/>
              <img src="./assets/images/profiles/carlos/egfr-over-time-state-3.png" id="section-5-state-3"
                class="update-path graph" alt="Graph showing eGFR after four years"/>
              <img src="./assets/images/profiles/carlos/egfr-over-time-state-4.png" id="section-5-state-4"
                class="update-path graph" alt="Graph showing eGFR after six years"/>
            </div>
            <div class="mobile-only">
              <img src="./assets/images/profiles/carlos/mobile/egfr-over-time-state-1-mobile.png" id="section-5-state-1"
                class="update-path mobile-graph graph visible" alt="Graph modeling eGFR decline over time, starting at biopsy"/>
              <img src="./assets/images/profiles/carlos/mobile/egfr-over-time-state-2-mobile.png" id="section-5-state-2"
                class="update-path mobile-graph graph" alt="Graph showing eGFR after two years"/>
              <img src="./assets/images/profiles/carlos/mobile/egfr-over-time-state-3-mobile.png" id="section-5-state-3"
                class="update-path mobile-graph graph" alt="Graph showing eGFR after four years"/>
              <img src="./assets/images/profiles/carlos/mobile/egfr-over-time-state-4-mobile.png" id="section-5-state-4"
                class="update-path mobile-graph graph" alt="Graph showing eGFR after six years"/>
            </div>
          </div>
        </div>

        <div class="slider-container">
          <div class="tablet-desktop-only">
            <img src="./assets/images/profiles/over-time-slider-1.svg" id="section-5-state-1"
              class="update-path slider-lower slider visible" alt="Slider shown at biopsy stage"/>
            <img src="./assets/images/profiles/over-time-slider-2.svg" id="section-5-state-2"
              class="update-path slider-lower slider" alt="Slider shown at 2 years"/>
            <img src="./assets/images/profiles/over-time-slider-3.svg" id="section-5-state-3"
              class="update-path slider-lower slider" alt="Slider shown at 4 years"/>
            <img src="./assets/images/profiles/over-time-slider-4.svg" id="section-5-state-4"
              class="update-path slider-lower slider" alt="Slider shown at 6 years"/>
          </div>
          <div class="mobile-only">
            <img src="./assets/images/profiles/over-time-slider-1-mobile.png" id="section-5-state-1"
              class="update-path slider-lower mobile-graph slider visible" alt="Slider shown at biopsy stage"/>
            <img src="./assets/images/profiles/over-time-slider-2-mobile.png" id="section-5-state-2"
              class="update-path slider-lower mobile-graph slider" alt="Slider shown at 2 years"/>
            <img src="./assets/images/profiles/over-time-slider-3-mobile.png" id="section-5-state-3"
              class="update-path slider-lower mobile-graph slider" alt="Slider shown at 4 years"/>
            <img src="./assets/images/profiles/over-time-slider-4-mobile.png" id="section-5-state-4"
              class="update-path slider-lower mobile-graph slider" alt="Slider shown at 6 years"/>
          </div>

          <input type="range" class="range-slider" id="s6-lower" name="s6-lower" min="1" max="4" value="1" step="1" />
        </div>
      </div>

      <div class="footnotes">
        <p>The graphic shown above is for illustrative purposes only and is intended to educate on potential
          histopathological changes that could occur during IgAN. It is not intended to provide specific information
          about the progression of these changes or inform treatment decisions. Changes in proteinuria and eGFR are
          hypothetical and are based on trends seen in clinical trials and cohort studies.<sup>3-6</sup></p>
        <p>*Image used with permission from the Renal Fellow Network, from: Gallan A. Kidney Biopsy of the Month.
          Published July 29, 2019. Available at <a class="format-url link-color" target="_blank"
            href="https://www.renalfellow.org/2019/07/29/kidney-biopsy-of-the-month-iga-nephropathy/">https://www.renalfellow.org/2019/07/29/kidney-biopsy-of-the-month-iga-nephropathy/</a>.
        </p>
        <p><sup>a</sup>PAS staining showing sclerosis in the upper left portion of the glomerulus as indicated by black
          arrow. A single glomerulus may not capture all components of the MEST-C score.</p>
        <p>ECM, extracellular matrix; eGFR, estimated glomerular filtration rate; Gd-IgA1, galactose-deficient IgA1; MEST-C, mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental sclerosis (S), tubular atrophy and interstitial fibrosis (T), crescent (C); PAS, periodic acid-Schiff.</p>
        <p><span class="bold">References: 1.</span> Lai KN, et al. <em>Nat Rev Dis Primers</em>. 2016;2:16001. <span
            class="bold">2.</span> Barratt J, et al. <em>Kidney Int</em>. 2023;103(2):391-402. <span
            class="bold">3.</span> Pitcher D, et al. <em>Clin J Am Soc Nephrol</em>. 2023;18(6):727-738. <span
            class="bold">4.</span> Faucon AL, et al. <em>Nephrol Dial Transplant</em>. 2024;30:gfae085. <span
            class="bold">5.</span> Rovin BH, et al. <em>Lancet</em>. 2023;402(10417):2077-2090. <span
            class="bold">6.</span> Lafayette R, et al. <em>Lancet</em>. 2023;402:859-870.</p>
      </div>
    </section>

    <section class="gray-bg" data-section-id="6" data-section-name="Carlos Impact of MEST-C Lesions" data-dot-label="Impact of <br>MEST-C Lesions">
      <div class="flex-header">
        <img src="./assets/images/profiles/carlos-profile.png" class="update-path bio-pic desktop-only" alt="" />

        <div>
          <h1 class="pat-header">Impact of <span class="nowrap">MEST-C</span> Lesions</h1>
          <p class="desc-text">MEST-C lesions may help nephrologists determine the appropriate management strategy for each patient.</p>
        </div>
      </div>

      <p class="bold">Click below to learn more about <span class="nowrap">MEST-C</span> lesions.</p>

      <div id="content-box">

        <div class="hotspot-container">
          <div class="content-hotspot" id="content-state-1"></div>
          <div class="content-hotspot" id="content-state-2"></div>
        </div>

        <div class="large-screens-only">
          <img src="./assets/images/profiles/carlos/sect-6-box-state-1.png" id="content-state-1"
            class="content-img visible update-path" alt="Illustration of inflammatory lesions (mesangial and endocapillary hypercellularity), impairing glomerular filtration." />
          <img src="./assets/images/profiles/carlos/sect-6-box-state-2.png" id="content-state-2"
            class="content-img update-path" alt="Illustration of chronic lesions (segmental glomerulosclerosis and tubular atrophy), indicating chronic irreversible loss of kidney function" />
        </div>
        <div class="mobile-only">
          <img src="./assets/images/profiles/carlos/mobile/sect-6-box-state-1-mobile.png" id="content-state-1"
            class="content-img mobile-graph visible update-path" alt="Illustration of inflammatory lesions (mesangial and endocapillary hypercellularity), impairing glomerular filtration." />
          <img src="./assets/images/profiles/carlos/mobile/sect-6-box-state-2-mobile.png" id="content-state-2"
            class="content-img mobile-graph update-path" alt="Illustration of chronic lesions (segmental glomerulosclerosis and tubular atrophy), indicating chronic irreversible loss of kidney function" />
        </div>

      </div>

      <div class="footnotes tablet-desktop-only">
          <p>CKD, chronic kidney disease; IgA, immunoglobulin A; MEST-C mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental sclerosis (S), tubular atrophy and interstitial fibrosis (T) and crescents (C).</p>
          <p><span class="bold">Reference: 1.</span> Pattrapornpisut P, et al. <em>Am J Kidney Dis</em>. 2021;78(3):429-441. <span class="bold">2.</span> Wendt R, et al. <em>Biomedicines</em>. 2024;12(10):2259. <span class="bold">3.</span> Trimarchi H, et al. <em>Kidney Int</em>. 2017;91(5):1014-1021. <span class="bold">4.</span> Mitrotti A, et al. <em>Pediatr Nephrol</em>. 2024;39(6):1685-1707. <span class="bold">5.</span> Filippone EJ, et al. <em>Front Immunol</em>. 2024;15:1436923. <span class="bold">6.</span> Wendt R, et al. <em>Biomedicines</em>. 2024;12(10):2259. <span class="bold">7.</span> Caster DJ, et al. <em>Kidney Int Rep</em>. 2023;8(9):1792-1800.</p>
      </div>
    </section>

    <section class="gray-bg acc-section" data-section-id="7" data-section-name="Carlos Impact of eGFR Decline on Progression to ESKD" data-dot-label="Impact of eGFR<br>Decline on<br>Progression">

      <div class="acc-header">
        <p>Learn more about how Carlos&rsquo; eGFR may decline over time</p>
        <img src="./assets/images/acc-arrow.svg" class="update-path acc-arrow" alt=""/>
      </div>

      <div class="acc-content">
        <div class="flex-header">
          <img src="./assets/images/profiles/carlos-profile.png" class="update-path bio-pic desktop-only" alt="" />
  
          <div>
            <h1 class="pat-header">Impact of eGFR Decline<br class="desktop-only" /> on Progression to Kidney Failure</h1>
            <p class="desc-text">Based on how quickly Carlos&rsquo; eGFR declines, he may reach<br class="desktop-only" />
              kidney failure within 10 years.</p>
          </div>
        </div>
  
        <p class="bold">If Carlos&rsquo; eGFR decline stabilizes, this can delay the onset of kidney failure.</p>
        <p class="direction">Select a button below to see how different rates of eGFR decline can impact progression to
          kidney failure.</p>
  
        <div class="graph-container">
          <div class="tablet-desktop-only">
            <img src="./assets/images/profiles/carlos/section-7-graph-state-0.png" id="0" class="update-path graph"
              alt="Graph depicting changes in eGFR over time" />
            <img src="./assets/images/profiles/carlos/section-7-graph-state-1.png" id="state-3" class="update-path visible graph"
              alt="Graph depicting changes in eGFR over time at a loss of 5 mL/min/1.73 m2 per year" />
            <img src="./assets/images/profiles/carlos/section-7-graph-state-2.png" id="state-2" class="update-path graph"
              alt="Graph depicting changes in eGFR over time at a loss of 3 mL/min/1.73 m2 per year" />
            <img src="./assets/images/profiles/carlos/section-7-graph-state-3.png" id="state-1" class="update-path graph"
              alt="Graph depicting changes in eGFR over time at a loss of 2 mL/min/1.73 m2 per year" />
            </div>
            <div class="mobile-only">
            <img src="./assets/images/profiles/carlos/mobile/section-7-graph-state-0-mobile.png" id="0" class="update-path mobile-graph graph"
              alt="Graph depicting changes in eGFR over time" />
            <img src="./assets/images/profiles/carlos/mobile/section-7-graph-state-1-mobile.png" id="state-3" class="visible update-path mobile-graph graph"
              alt="Graph depicting changes in eGFR over time at a loss of 5 mL/min/1.73 m2 per year" />
            <img src="./assets/images/profiles/carlos/mobile/section-7-graph-state-2-mobile.png" id="state-2" class="update-path mobile-graph graph"
              alt="Graph depicting changes in eGFR over time at a loss of 3 mL/min/1.73 m2 per year" />
            <img src="./assets/images/profiles/carlos/mobile/section-7-graph-state-3-mobile.png" id="state-1" class="update-path mobile-graph graph"
              alt="Graph depicting changes in eGFR over time at a loss of 2 mL/min/1.73 m2 per year" />
          </div>
  
          <div class="hotspot" id="state-1" data-value="Annual eGFR loss: -2 mL/min/1.73 m^2/year"></div>
          <div class="hotspot" id="state-2" data-value="Annual eGFR loss: -3 mL/min/1.73 m^2/year"></div>
          <div class="hotspot" id="state-3" data-value="Annual eGFR loss: -5 mL/min/1.73 m^2/year"></div>
  
          <div class="upper-hotspots">
            <div class="hotspot lower-hotspot" id="state-3" data-value="Annual eGFR loss: -5 mL/min/1.73 m^2/year"></div>
            <div class="hotspot lower-hotspot" id="state-2" data-value="Annual eGFR loss: -3 mL/min/1.73 m^2/year"></div>
            <div class="hotspot lower-hotspot" id="state-1" data-value="Annual eGFR loss: -2 mL/min/1.73 m^2/year"></div>
          </div>
        </div>
  
        <div class="footnotes">
          <p>CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate.</p>
        </div>
      </div>

    </section>

    <section class="switch-pat-section" data-section-name="Switch Patient">
      <h2 class="yellow-header">SELECT ANOTHER HYPOTHETICAL PATIENT</h2>

      <div class="flex">
        <div class="profile nav-el" data-nav-url="progression/sarah" data-exit-url="progression/sarah">
          <img src="./assets/images/profiles/sarah-profile.png" class="update-path" alt="" />
          <h3>Sarah</h3>
        </div>
        <div class="profile nav-el" data-nav-url="progression/mark" data-exit-url="progression/mark">
          <img src="./assets/images/profiles/mark-profile.png" class="update-path" alt="" />
          <h3>Mark</h3>
        </div>
      </div>

      <img src="./assets/images/or-line-graphic.png" class="or-line update-path" alt="Or" />

      <div class="button nav-el" id="discover" data-nav-url="pathogenesis/index" data-exit-url="pathogenesis/mark">
        <p>Discover the pathogenesis of IgAN</p>
      </div>
    </section>

    {{> ../templates/footer-el }}

  </main>

  <script type="text/javascript" src="../static.bundle.js" charset="utf-8"></script>
</body>

</html>